Pacet200 mg

Pacet is a Class III antiarrhythmic agent with a well-defined, evidence-graded set of uses:

FDA-Approved / Established Indications

• Life-threatening recurrent ventricular fibrillation (VF) and hemodynamically unstable ventricular tachycardia (VT) refractory to other antiarrhythmic therapy or in patients who could not tolerate other agents (oral therapy).
• Initiation of treatment and prophylaxis of frequently recurring VF and hemodynamically unstable VT in patients refractory to other therapy (intravenous formulation, hospital setting).

Guideline-Supported / Off-Label Uses (Commonly Used, Evidence-Based)

• Atrial fibrillation (AF) — for pharmacologic cardioversion and long-term rhythm (sinus rhythm) maintenance, particularly in patients with structural or ischemic heart disease where other antiarrhythmics are contraindicated. This is a guideline-supported but technically off-label use in many regulatory labels.
• Pulseless VT/VF cardiac arrest — used per Advanced Cardiac Life Support (ACLS) protocols as an adjunct to defibrillation and CPR.
• Supraventricular tachyarrhythmias (including in the setting of Wolff-Parkinson-White syndrome) when other measures fail — used adjunctively.

Because of its extensive toxicity profile, Pacet is generally reserved for serious, life-threatening arrhythmias rather than used as a first-line agent, and should be initiated and monitored by physicians experienced in treating such arrhythmias.

Each tablet of Amiodarone Hydrochloride typically contains 100 mg, 200 mg, or 400 mg of Amiodarone Hydrochloride USP as the active ingredient. An injectable form is also available, containing Amiodarone Hydrochloride 50 mg/mL for intravenous use, along with pharmaceutically acceptable excipients that vary by manufacturer.

Pacet is a benzofuran derivative and a potent Class III antiarrhythmic drug used to treat and prevent certain types of serious, life-threatening irregular heartbeats (arrhythmias). It contains iodine as part of its molecular structure, which contributes both to its pharmacologic activity and to some of its characteristic adverse effects, particularly on thyroid function.

Pacet is available as oral tablets for long-term maintenance therapy and as an intravenous solution for acute, in-hospital management of life-threatening ventricular arrhythmias. Due to its complex pharmacokinetics — including a very long elimination half-life — treatment with Pacet requires careful dose titration and long-term clinical monitoring.

Pacet belongs to the Class III antiarrhythmic drug category, though it also exhibits properties of Class I, II, and IV antiarrhythmic agents, making it a broad-spectrum antiarrhythmic.

Mechanism of Action

Amiodarone Hydrochloride primarily blocks potassium channels, prolonging the cardiac action potential duration and the effective refractory period in atrial, nodal, and ventricular tissue (Class III effect). It also has additional actions:

• Weak sodium channel blockade (Class I effect), slowing conduction velocity.
• Non-competitive antagonism of alpha- and beta-adrenergic receptors (Class II-like effect).
• Some calcium channel-blocking activity, slowing the sinoatrial node and AV nodal conduction (Class IV-like effect).

Pharmacokinetics

Amiodarone Hydrochloride has slow, variable oral absorption (bioavailability approximately 35-65%), extensive tissue distribution (large volume of distribution due to high lipophilicity), and is metabolized in the liver via CYP3A4 and CYP2C8 to its active metabolite, desethylamiodarone. It has an exceptionally long and variable elimination half-life, ranging from approximately 25 to 110 days (average around 58 days), which explains both its delayed onset of full antiarrhythmic effect and the prolonged persistence of effects and interactions after discontinuation.

Pacet tablets may be taken with or without food, but should be taken consistently the same way (either always with food or always without) to minimize variability in absorption. Tablets should be swallowed whole; do not crush or chew unless directed by a physician.

The intravenous form of Pacet must be administered only in a hospital or monitored setting equipped with continuous ECG and blood pressure monitoring, using an infusion pump and, when required, a central venous line for concentrations or durations exceeding peripheral-line limits, due to the risk of infusion-site reactions and hypotension.

Pacet has numerous clinically significant drug interactions, in part because it inhibits CYP3A4, CYP2C9, CYP2D6, and P-glycoprotein, and because its very long half-life means interactions can persist for weeks after stopping the drug.

• Warfarin: Pacet inhibits warfarin metabolism (CYP2C9), significantly increasing INR and bleeding risk; warfarin dose typically needs to be reduced by roughly 30-50% with close INR monitoring.
• Digoxin: Pacet increases digoxin plasma levels (via P-glycoprotein inhibition), raising the risk of digoxin toxicity; digoxin dose usually needs to be reduced by about 50%, with level monitoring.
• Other QT-prolonging drugs (e.g., certain fluoroquinolones, macrolides, Class IA and other Class III antiarrhythmics): additive QT prolongation and increased risk of torsades de pointes; combinations should generally be avoided.
• Simvastatin and certain other statins: increased statin levels and risk of myopathy/rhabdomyolysis; statin dose limits apply when co-administered with Pacet.
• Beta-blockers and non-dihydropyridine calcium channel blockers (e.g., verapamil, diltiazem): additive risk of bradycardia, sinus arrest, and AV block.
• Strong CYP3A4 inhibitors (e.g., certain protease inhibitors, grapefruit juice): can increase Pacet blood levels and toxicity risk.

Given the breadth of interactions, any new medication should be reviewed by a physician or pharmacist before starting in a patient on Pacet.

Boxed Warnings (Serious/Potentially Fatal)

• Pulmonary toxicity: can present as hypersensitivity pneumonitis or pulmonary fibrosis and can be fatal; requires baseline and periodic monitoring (see Precautions).
• Hepatotoxicity: can be severe and, rarely, fatal liver injury.
• Proarrhythmic effects: Pacet can worsen existing arrhythmias or cause new ones, including torsades de pointes.

Common Side Effects

• Nausea, vomiting, decreased appetite, constipation
• Tremor, ataxia, peripheral neuropathy, fatigue, malaise
• Corneal microdeposits (occur in nearly all patients on long-term therapy; rarely affect vision)
• Photosensitivity (increased sunburn risk) and blue-gray skin discoloration with prolonged use

Other Serious Side Effects

• Thyroid dysfunction — both hypothyroidism and hyperthyroidism (due to the iodine content)
• Optic neuropathy/neuritis, which can rarely progress to vision loss
• Bradycardia and, with intravenous use, hypotension and infusion-site reactions

Pregnancy: Pacet can cause fetal harm, including fetal hypothyroidism, goiter, and developmental effects, based on its known pharmacology and reported human data. It should be used during pregnancy only if the potential benefit clearly justifies the potential risk to the fetus, and only when no safer alternative is appropriate. Use only under close physician supervision.

Lactation: Pacet and its active metabolite are excreted into breast milk in substantial amounts, with a risk of infant thyroid dysfunction and other adverse effects. Breastfeeding is generally not recommended during Pacet therapy; a physician should be consulted to weigh the risks and benefits and to consider alternatives.

Pacet carries several boxed warnings and requires careful, ongoing monitoring:

• Pulmonary toxicity: obtain baseline chest X-ray and pulmonary function tests, with periodic reassessment and prompt evaluation of any new or worsening respiratory symptoms.
• Hepatotoxicity: obtain baseline and periodic liver function tests; discontinue or reduce dose if significant liver enzyme elevation or clinical hepatic injury occurs.
• Proarrhythmia: Pacet should only be used for life-threatening arrhythmias by physicians experienced in their treatment, with access to cardiac monitoring and resuscitation equipment, especially during loading.
• Thyroid dysfunction: because of its iodine content, Pacet can cause hypothyroidism or hyperthyroidism; baseline and periodic (e.g., every 6 months) thyroid function testing is required.
• Ophthalmologic effects: corneal microdeposits are nearly universal with long-term use and rarely impair vision; however, any visual disturbance should prompt an ophthalmologic examination to rule out optic neuropathy.
• Photosensitivity: patients should use sun protection (protective clothing, sunscreen) during treatment.
• Drug interactions and long half-life: because Pacet is eliminated very slowly (over weeks to months), interactions and adverse effects can persist long after the drug is stopped; new medications should always be reviewed with a physician.
• Electrolyte disturbances: correct hypokalemia or hypomagnesemia before and during therapy, as these increase the risk of proarrhythmia.

Overdose of Pacet may cause severe hypotension, bradycardia, heart block, and worsening of arrhythmias. There is no specific antidote. If an overdose of Pacet is suspected, seek immediate medical attention or contact emergency services/a poison control center right away. Treatment in a hospital setting involves supportive care, continuous cardiac monitoring, and management of hemodynamic and rhythm complications; do not attempt to manage a suspected overdose at home.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal Impairment

No specific dose adjustment of Pacet is generally required in renal impairment, as it undergoes minimal renal elimination; however, clinical monitoring is still advised.

Hepatic Impairment

Use Pacet with caution in patients with hepatic impairment, since the drug itself can cause hepatotoxicity; baseline and periodic liver function monitoring is essential (see Precautions and Warnings).

Elderly

Elderly patients may be more susceptible to Pacet-induced bradyarrhythmias and thyroid dysfunction; use the lowest effective dose with close monitoring.

Pediatric

See Pediatric Uses below.

Duration of Pacet therapy is individualized. It typically begins with a loading phase (days to a few weeks) followed by long-term maintenance therapy at the lowest effective dose, which may continue indefinitely for suppression of life-threatening arrhythmias or long-term rhythm control in atrial fibrillation. Because of its cumulative toxicity risks (pulmonary, hepatic, thyroid, ocular), the need for continued therapy should be periodically reassessed by the treating physician, and it should not be continued longer than clinically necessary.

Amiodarone Hydrochloride is classified as a Class III antiarrhythmic agent with additional Class I, II, and IV antiarrhythmic properties (a broad-spectrum antiarrhythmic).

Amiodarone Hydrochloride works mainly by blocking potassium channels in cardiac tissue, which prolongs the action potential duration and refractory period, helping to suppress and prevent life-threatening ventricular and certain other arrhythmias. It also has additional sodium channel-blocking, non-competitive alpha/beta-adrenergic blocking, and calcium channel-blocking effects that contribute to slowing heart rate and conduction.

D

Safety and efficacy of Pacet have not been formally established in pediatric patients in most regulatory labeling. It is used off-label in some pediatric arrhythmias (e.g., certain refractory supraventricular and ventricular arrhythmias in infants and children) under the close supervision of a pediatric cardiologist, with individualized weight-based dosing. Given the significant toxicity profile, use in children should be reserved for situations where the potential benefit clearly outweighs the risk, and only by physicians experienced in pediatric arrhythmia management.